Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Objective To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.Methods Patients refractory to ≥1 biological disease-modifying antirheumatic drug (DMARD) received upadacitinib 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/3/e003918.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rmdopen.bmj.com/content/10/3/e003918.full

Similar Items